TH March partners with Novidea to drive digital transformation with end-to-end, cloud-based broker platform


Novidea® today announces that it has partnered with the UK’s leading jewellery insurance broker, TH March, to implement its born-in-the-cloud, data-driven insurance platform. The platform will manage their complete end-to-end customer journeys for both high volume personal lines and large complex commercial risks placed into the London Market, all on one platform, with an integrated customer self-service portal.

Further, around two thirds of TH March’s growing personal jewellery insurance products are currently arranged by its call centre and a third via online enquiries. The new Novidea online portal will invert this to two thirds portal and one third call centre, so that TH March’s professional team can focus their efforts on High Net Worth and more complex accounts, with enhanced customer experience and operational efficiencies for both existing personal and business customers.

Andrew Alcock, Chief Operating Officer, TH March said: “We selected Novidea as we were keen to work with tomorrow’s technology. Looking ahead, Novidea’s cloud-based customer service portal will give us the edge to ensure we retain our market-leading position, by giving both our personal lines and business customers a much-enhanced customer experience and more efficient service, which is so important in today’s on-demand world.

“Although we were established in 1887, we have always been an innovative business. Novidea’s platform will be transformational, with all our six UK offices moving away from siloed legacy systems to one shared, data- driven platform, with integrated customer and business data and Management Information.”

Ben Potts, MD, UK, Novidea said: “Historically, the insurance market has been encumbered by legacy systems that are difficult and expensive to update, with limited access to real-time Management Information. Today, forward- looking businesses, like TH March, are increasingly moving to cloud-based platforms that enable them to automate processes, reduce costs, add agility, and boost customer service standards.”

The portal will ultimately enable TH March customers buying their March Plus product to manage all aspects of their insurances securely online, including policy information, mid-term adjustments, claims, renewals, contact details, and more. The portal will seamlessly integrate with Novidea’s end-to-end insurance platform, so that TH March’s team has access to live customer data from first enquiry to quote and bind, and claims.

Further, Novidea has partnered with Polaris, whose imarket product and digital trading standards are used market-wide by insurers, brokers, and software houses. This will enable TH March to offer major customers a one-stop shop for all their insurance needs, complimenting complex jewellers block risks placed via Lloyd’s and the London Market with e-traded cyber business insurance products.


Data Mining will Become Essential to Reduce the Disease Burden and Empower Healthcare Stakeholders


With the rising number of stakeholders playing a role in medical decision-making, pharmaceutical companies are looking for more effective ways to communicate the value of an innovative treatment. They are increasingly turning to actionable, evidence-based programs to convince these stakeholders of the value of the treatment. A comprehensive data set can help an analytics team map a treatment journey and quickly identify the patients and physicians who are most likely to benefit from a novel therapy.

Frost & Sullivan’s latest executive brief, The Most Effective Way to Identify Better Outcomes When Using Limited Patient Populations, examines how analyzing predictable patterns in the patient journey can help commercial teams identify patients who can benefit from novel therapies.

To download the complimentary executive brief, please visit:

“Due to the complexity of identifying rare diseases, new methodologies and data mining approaches are necessary,” observed Dennis Kimmel, Senior Consultant, Life Sciences at Frost & Sullivan. “The information relayed to a commercial team must generate accurate and timely alerts regarding a patient cohort so the therapy can be optimally effective. This means that the intelligence the commercial teams receive must be patient-centric and cohort-specific. In such a scenario, innovative and validated software that can analyze isolated data sets from a multitude of databases will prove crucial.”

“We believe that smarter, more innovative use of data and analytics is essential for reducing the global burden of disease,” noted Aswin Chandrakantan, MD, Chief Medical Officer at Komodo Health. “Rich and nuanced data is the key to predictive solutions that can empower a multitude of healthcare stakeholders, including life science companies, healthcare payers and providers, and patient advocacy groups, to create a more cost-effective, value-driven healthcare system.”

In this multibillion-dollar industry, a company may only have limited experience with a disease or be entering a completely new therapeutic area; a succinct alert map of patient encounter data is a valuable asset. Commercial teams should evaluate a mapping vendor based on:

  • Broad visibility: A deep data ecosystem that captures diverse signals for large populations and an array of clinical encounters.
  • Accuracy: Data modeling that eliminates false negatives and positives in alerts.
  • Speed: The frequency of alerts on patient treatment at optimal phases.
  • Evolution: New features in alerting software and new data sources that continually elevate the system.
  • Expertise: Years of experience in identifying highly complex patient cohorts and translating clinical patient journeys.